Rankings
▼
Calendar
BMY Q4 2024 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena
BMY
Bristol-Myers Squibb Company
$124B
Q4 2024 Earnings
Healthcare
Drug Manufacturers - General
Income Statement
Revenue
$12.3B
+7.5% YoY
Gross Profit
$7.4B
60.2% margin
Operating Income
$2.5B
20.5% margin
Net Income
$72M
0.6% margin
EPS (Diluted)
$0.04
QoQ Revenue Growth
+3.8%
Cash Flow
Operating Cash Flow
$4.4B
Free Cash Flow
$4.1B
Stock-Based Comp.
$120M
Balance Sheet
Total Assets
$92.6B
Total Liabilities
$76.2B
Stockholders' Equity
$16.3B
Cash & Equivalents
$10.3B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$12.3B
$11.5B
+7.5%
Gross Profit
$7.4B
$6.5B
+14.4%
Operating Income
$2.5B
$2.0B
+29.7%
Net Income
$72M
$1.8B
-95.9%
Revenue Segments
Eliquis
$3.2B
26%
Opdivo
$2.5B
20%
Revlimid
$1.3B
11%
Orencia
$1.0B
8%
Pomalyst/Imnovid
$823M
7%
Yervoy
$675M
5%
Reblozyl
$547M
4%
Other Growth Brands
$512M
4%
Breyanzi
$263M
2%
Opdualag
$254M
2%
Other Legacy Brands
$250M
2%
Camzyos
$223M
2%
Sprycel
$198M
2%
Abraxane
$174M
1%
Zeposia
$158M
1%
Abecma
$105M
1%
Sotyktu
$83M
1%
Krazati
$39M
0%
Geographic Segments
UNITED STATES
$8.6B
70%
Rest Of World
$3.4B
28%
Other Region
$350M
3%
← FY 2024
All Quarters
Q1 2025 →